Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Nephrology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Why Are You Still Avoiding PD in Older Adults? An Interactive Case Study
June 2025
For elderly patients, survival duration between hemodialysis and peritoneal dialysis, even when statistically significant, is usually in…
Read more
25 Jun 2025
Why Are You Still Avoiding PD in Older Adults? An Interactive Case Study
For elderly patients, survival duration between hemodialysis and peritoneal dialysis, even when statistically significant, is usually in…
2
Mins
24 Jun 2025
Interview: Rainer Oberbauer
I’ve been in the field for almost 30 years now. I started by chance after my postdoctoral training. I became interested in kidney…
11
Mins
12 Jun 2025
Characterising Drug-Associated Nephrolithiasis
Kidney stones are the most common condition affecting the urinary system, impacting approximately 8–12% of the global population…
4
Mins
14 Feb 2025
Lupus Vasculitis, A Rare Diagnosis and a Therapeutic Challenge
More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may manifest with…
7
Mins
12 Dec 2024
Targeting IgAN with Sparsentan + a SGLT2i
IgA nephropathy (IgAN) can impact life expectancy in those affected, thus efficacious treatment is key. Endothelin 1 (ET-1) and angiotensin…
31 Oct 2024
Tackling Infectious Diseases
This interactive article summarises key discussions from GSK sponsored symposia that took place during the ESCMID Global Congress 2024, held from 27–30th April 2024 in Barcelona, Spain.
10
Mins
24 Oct 2024
Advances in proteinuria-targeting therapy in IgAN
Advances in Therapy to Address Proteinuria in Patients with Immunoglobulin A Nephropathy. As the majority of patients with IgA…
7
Mins
23 Aug 2024
Proliferative Lupus Nephritis with Focal Extracapillary Proliferation in Latin America
This study investigates the impact of extracapillary proliferation in proliferative lupus nephritis on remission rates in patients.
Loading posts...
1
2
3
…
20
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View